Mochi Health Pricing Analysis & Total Cost

What Mochi Health Actually Charges

Mochi Health operates on a membership-plus-medication model common across telehealth weight-loss platforms. The membership fee covers provider consultations, ongoing check-ins, and care coordination. Medication costs are billed separately, either through insurance or a partner compounding pharmacy.

The membership itself runs $49 to $99 per month depending on the service tier. Lower-tier plans typically include asynchronous messaging with a provider and monthly check-ins. Higher-tier options add video visits and more frequent touchpoints. These fees are comparable to what platforms like Calibrate ($149/month) and Found ($129/month for medication-inclusive plans) charge, though direct comparisons require examining what each fee actually covers.

Medication is the larger variable. Patients prescribed compounded semaglutide through Mochi's pharmacy partners can expect to pay approximately $150 to $350 per month, depending on dose titration. A patient starting at 0.25 mg weekly and titrating to 2.4 mg over 16 to 20 weeks will see costs increase as the dose rises. Compounded GLP-1 medications are not FDA-approved as finished products, a distinction the FDA has addressed in guidance documents regarding 503A and 503B compounding pharmacies.

For patients with commercial insurance that covers brand-name GLP-1 receptor agonists, Mochi can prescribe Wegovy (semaglutide 2.4 mg) or Zepbound (tirzepatide). In these cases, the medication copay depends entirely on the patient's plan. Novo Nordisk's savings card can reduce Wegovy copays to as low as $0 for eligible commercially insured patients, while Eli Lilly offers a similar program for Zepbound.

The Real Cost of Compounded Semaglutide

Compounded semaglutide represents Mochi's most accessible price point for uninsured or underinsured patients. The pricing deserves careful examination because the compounded drug market lacks the standardized pricing of branded pharmaceuticals.

Compounding pharmacies that operate under Section 503B of the Federal Food, Drug, and Cosmetic Act can produce semaglutide injections in bulk without individual patient prescriptions, though these products have not undergone FDA review for safety, efficacy, or manufacturing quality as finished drugs. The price advantage is significant: $150, $350/month for compounded vs. $1,349/month retail for brand-name Wegovy. The tradeoff involves accepting a product with less regulatory oversight.

A 2024 FDA safety communication warned about adverse events linked to compounded semaglutide products, including dosing errors and contamination concerns. Patients considering compounded options should ask their provider which specific 503B outsourcing facility supplies the medication and whether that facility has passed its most recent FDA inspection.

The dose-titration schedule also affects cumulative cost. The standard Wegovy titration protocol starts at 0.25 mg weekly for 4 weeks, then increases through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg. Each dose increase may correspond to a price increase from the compounding pharmacy. A patient who reaches maintenance dose by month 5 could see their monthly compounded medication cost stabilize around $250, $350, meaning the first-year total (membership plus medication) often falls between $3,600 and $5,400.

Insurance Coverage: What Gets Approved and What Doesn't

Insurance acceptance is one of Mochi Health's differentiators from cash-only competitors like Hims & Hers Weight Loss or some direct-to-consumer compounding platforms. Whether this advantage translates to lower costs depends on what specific medications a patient's plan covers.

The coverage picture for GLP-1 receptor agonists has shifted rapidly. According to a 2024 KFF employer survey, approximately 40% of large employers covered GLP-1 medications for weight loss, up from an estimated 25 to 30% in 2023. Among those that do cover the drugs, prior authorization requirements are nearly universal, typically requiring documented BMI ≥30 kg/m² (or ≥27 kg/m² with at least one weight-related comorbidity), evidence of failed lifestyle modification, and sometimes a failed trial of an older weight-loss medication.

Mochi's care team handles prior authorization submissions, which is included in the membership fee. This is a meaningful service: prior authorization for GLP-1 medications involves clinical documentation that many primary care offices struggle to compile efficiently. The American Medical Association's 2024 prior authorization survey found that 94% of physicians reported care delays associated with prior authorization, and 80% reported that prior authorization requirements led to treatment abandonment.

For Medicare Part D beneficiaries, the picture is different. Medicare does not currently cover anti-obesity medications, though the Treat and Reduce Obesity Act has been reintroduced in Congress. Mochi patients on Medicare would need to pay cash for compounded semaglutide or brand-name medications at full retail price.

Mochi Health vs. Competitor Pricing

A pricing analysis is incomplete without comparing Mochi to the alternatives patients are actually evaluating. The telehealth weight-loss market has become crowded, and pricing structures vary widely.

Ro Body: Charges $99/month for its GLP-1 program, which includes provider visits, metabolic testing, and compounded semaglutide. Medication costs start around $145/month. Total first-month cost is approximately $244. Ro does not currently bill insurance for GLP-1 medications.

Hims & Hers: Offers compounded semaglutide starting at $199/month with the consultation fee bundled into the medication price. Their model is simpler to understand (one price), though less flexible for patients who want insurance billing.

Calibrate: A higher-touch program at $149/month for a one-year commitment, plus medication costs. Calibrate focuses on metabolic health coaching alongside GLP-1 prescribing and does work with insurance for brand-name medications.

Sequence (acquired by WW): Previously charged $99/month for membership plus insurance-billed medication. Following the acquisition, pricing and availability have been in flux.

Mochi Health sits in the middle of this range. Its membership fee is lower than Calibrate's but comparable to Ro Body's. The compounded medication pricing is competitive with Hims & Hers once you add the membership fee. Mochi's insurance billing capability gives it an edge over cash-only platforms for patients with qualifying coverage.

For a patient comparing total annual costs using compounded semaglutide at maintenance dose:

• Mochi: $3,600, $5,400 (membership + compounded medication)
• Ro Body: $2,928, $4,500 (membership + compounded medication)
• Hims & Hers: $2,388, $4,788 (bundled pricing, dose-dependent)
• Calibrate: $5,388, $7,200+ (membership + medication, often insurance-billed)

These ranges shift constantly as platforms adjust pricing. The numbers above reflect publicly listed prices as of early 2026.

Clinical Evidence Behind Mochi's Prescribed Medications

The medications Mochi prescribes are well-studied, even if the compounded versions lack the same regulatory backing as their branded counterparts. Understanding the clinical trial data helps patients assess whether the cost is justified by expected outcomes.

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg weekly achieved 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo [1]. The STEP-5 extension trial demonstrated that weight loss was maintained over 104 weeks with continued treatment, with participants losing 15.2% of body weight vs. 2.6% for placebo [2].

For tirzepatide (Zepbound/Mounjaro), the SURMOUNT-1 trial (N=2,539) showed even larger effects. Participants on the highest dose (15 mg weekly) lost 22.5% of body weight at 72 weeks vs. 2.4% for placebo [3]. Dr. Ania Jastreboff, the trial's lead investigator at Yale School of Medicine, noted: "The magnitude of weight reduction observed with tirzepatide exceeds that seen with any previously studied anti-obesity medication."

The clinical question for Mochi patients paying for compounded semaglutide is whether the compounded product delivers equivalent bioavailability and efficacy. No head-to-head trials have compared compounded semaglutide to Novo Nordisk's Wegovy. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends FDA-approved formulations as first-line therapy and does not specifically endorse compounded alternatives [4].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "We do not have data on the purity, potency, or sterility of compounded semaglutide products. Patients should understand they are accepting a degree of uncertainty that does not exist with approved formulations."

What Mochi Health Prescribes Beyond GLP-1s

Mochi's formulary extends beyond semaglutide and tirzepatide. The platform may also prescribe metformin, bupropion/naltrexone (Contrave), topiramate, and other adjunctive medications depending on clinical presentation.

Metformin, an off-label option for weight management, costs $4, $30/month through most pharmacies and is often covered by insurance. A 2024 meta-analysis in Annals of Internal Medicine found that metformin produced modest weight loss of 2 to 3% body weight over 6 to 12 months, far less than GLP-1 receptor agonists but at a fraction of the cost [5].

Contrave (bupropion 90 mg/naltrexone 8 mg extended-release), which is FDA-approved for chronic weight management, showed 5 to 6% weight loss vs. 1.3% for placebo in the COR-I trial [6]. Generic formulations are available for $50, $150/month, while brand-name Contrave lists at approximately $300/month without insurance.

The ability to prescribe from a broader formulary means Mochi can offer step therapy or combination approaches. This may matter for patients who cannot tolerate GLP-1 side effects (nausea affects 40 to 44% of semaglutide patients in clinical trials) or who want to start with a less expensive first-line option before committing to GLP-1 therapy.

Hidden Costs and What the Membership Fee Doesn't Cover

Several potential costs fall outside Mochi's membership and medication pricing. Lab work is the most common. Most GLP-1 prescribers require baseline labs including fasting glucose, HbA1c, lipid panel, hepatic function, and renal function. These can be billed to insurance, but patients with high-deductible health plans may pay $100, $400 out of pocket for a comprehensive metabolic panel and HbA1c.

Some patients will need additional monitoring. The American Gastroenterological Association's 2024 guideline recommends screening for pancreatitis risk factors before starting GLP-1 therapy and periodic lipase monitoring in patients with symptoms [7]. If a patient develops gallbladder symptoms (cholelithiasis occurs in approximately 1.5 to 2.6% of patients on GLP-1 agonists per STEP trial data), imaging and potential surgical costs are the patient's responsibility.

Shipping costs for compounded medications vary by pharmacy partner. Some include free standard shipping; others charge $10, $15 per shipment. Expedited or cold-chain shipping (required for semaglutide in warm climates) may carry additional fees.

Weight regain after discontinuation is another cost consideration. The STEP-1 trial extension showed that participants regained two-thirds of their lost weight within one year of stopping semaglutide [2]. This means GLP-1 therapy is effectively an ongoing expense for most patients who want to maintain results, not a one-time course of treatment. A patient budgeting for Mochi should think in terms of years, not months.

Is Mochi Health Legitimate?

Mochi Health operates as a licensed telehealth platform with providers credentialed in the states where they practice. The company is not a pharmacy; it partners with external pharmacies for medication fulfillment. This is a standard model in telehealth, used by competitors including Ro, Hims & Hers, and Calibrate.

Legitimacy concerns in the GLP-1 telehealth space typically center on three issues: prescribing standards, compounding pharmacy quality, and refund policies. Mochi requires an intake questionnaire and provider consultation before prescribing, consistent with Federation of State Medical Boards (FSMB) guidelines on telemedicine. The company uses partner pharmacies registered with state boards of pharmacy, though patients should independently verify that any compounding pharmacy holds current FDA outsourcing facility registration.

Regarding patient satisfaction, Mochi Health reviews on third-party platforms like Trustpilot and Google show mixed feedback typical of telehealth GLP-1 providers. Common positive themes include convenience and responsive support. Common complaints involve medication delays, difficulty reaching providers for urgent questions, and confusion about billing. These patterns mirror complaints across the telehealth weight-loss industry rather than being unique to Mochi.

The Better Business Bureau and state medical board complaint databases are useful verification tools for patients doing due diligence. A telehealth company's legitimacy is best assessed not by marketing claims but by verifiable licensure, transparent pricing disclosures, and adherence to AMA telehealth practice guidelines.

Who Gets the Most Value From Mochi Health

The cost-benefit calculation for Mochi depends on a patient's specific insurance status, BMI, comorbidities, and geographic access to in-person obesity medicine specialists.

Patients most likely to benefit from Mochi's pricing model include those with commercial insurance that covers GLP-1 medications (reducing total cost to membership fee plus copay), those in areas with limited access to board-certified obesity medicine physicians (only about 5,800 are certified by the American Board of Obesity Medicine nationwide), and those who prefer the convenience of telehealth over in-person visits.

Patients who may find better value elsewhere include Medicare beneficiaries (who cannot use Mochi's insurance billing for anti-obesity medications), patients comfortable navigating compounding pharmacies directly (potentially cutting out the membership fee), and those who qualify for manufacturer savings programs through their primary care physician.

The 2024 Endocrine Society guideline recommends that pharmacotherapy for obesity be prescribed within a comprehensive treatment plan that includes dietary modification, physical activity, and behavioral counseling [4]. Patients should evaluate whether Mochi's membership tier provides sufficient behavioral and nutritional support or whether they need supplemental coaching, which would add to overall costs.

A 12-month budget projection for a typical Mochi patient using compounded semaglutide at maintenance dose: $99/month membership ($1,188/year) plus $250/month average medication ($3,000/year) plus $200 in labs equals approximately $4,388 total first-year cost.